Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review-Reference-Cited by-同舟云学术

Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review

Published:2021-01 Issue: Volume:157 Page:103193
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Lapidari Pietro,Vaz-Luis Ines,Di Meglio Antonio^ORCID

Funder

Susan G. Komen

Fondation Gustave Roussy

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference127 articles.

1. Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;Eur. J. Cancer,2010

2. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?;Aapro;Support. Care Cancer,2010

3. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review;Affentranger;Crit. Rev. Oncol. Hematol.,2019

4. Mecapegfilgrastim in chemotherapy-induced neutropenia: a profile of its use in China;Al-Salama;Clin. Drug Investig.,2019

5. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia;Biganzoli;Semin. Oncol.,2004

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of solid tumors;Cochrane Database of Systematic Reviews;2024-01-16

2. Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis;Blood;2023-12-21

3. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer;Supportive Care in Cancer;2023-09-20

4. Neutropenie – wann ist eine GCSF Unterstützung notwendig?;Aktuelle Urologie;2023-08-22

5. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial;The Lancet Respiratory Medicine;2023-01